CURRENT ORAL MUSCLE RELAXANTS IN THE COMBINATION THERAPY OF PAIN SYNDROMES


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper considers the treatment of central spasticity and myofascial pain syndromes with oral muscle relaxants and another therapy. It presents a number of recommendations for the management of patients of this gpoup. The data available in the literature data on spasticity treatment with oral muscle relaxants are given.

Full Text

Restricted Access

About the authors

A. Vasilyev

Central State Medical Academy, Department for Presidential Affairs of the Russian Federation

Email: alexvasiliev@mail.ru
Candidate of Medical Sciences

References

  1. Pandyan A., Gregoric M., Barnes M. et al. Spasticity: clinical perceptions, 367 neurological realities and meaningful measurement // Disabil. Rehabil. - 2005; 27: 2-6.
  2. Bhadra N. Neuroprostheses for spasticity control. In: Kilgore K, editor. Implantable neuroprostheses for restoring function / Cambridge: Elsevier, 2015; 331.
  3. Ertzgaard P., Anhammer M., Forsmark A. Regional disparities in botulinum toxin A (BoNT-A) therapy for spasticity in Sweden: budgetary consequences of closing the estimated treatment gap // Acta Neurol. Scand. - 2017; 135 (3): 366-72.
  4. Brainin M., Norrving B., Sunnerhagen K. et al. Poststroke chronic disease management: towards improved identification and interventions for poststroke spasticity-related complications // Int. J. Stroke. - 2011; 6: 42-6.
  5. Ryu J., Lee J., Lee S. et al. Factors predictive of spasticity and their effects on motor recovery and functional outcomes in stroke patients // Top Stroke Rehabil. - 2010; 17: 380-8.
  6. Jensen R., Olesen J. et al. Tension-type headache: an update on mechanisms and treatment // Cur. Opin. Neurol. - 2000; 13 (3): 285-9.
  7. Исайкин А.И., Кузнецов И.В., Кавелина А.В. и др. Фасеточный синдром: причины возникновения, клиника, диагностика и лечение // Consilium Medicum. (Прил.). - 2016; 2: 53-61.
  8. Deyo R., Weinstein J. Low Back Pain // N. Engl. J. Med. - 2001; 344 (5): 363-70.
  9. Henschke N., Maher C., Refshauge K. et al. Prevalence of and screening for serious spinal pathology in patient presenting to primary care settings with acute low back pain // Arthritis Rheum. - 2009; 60 (10): 3072-80. Doi: 10.1002/ art.24853
  10. Manchikanti L., Standiford Helm, Vijay Singh et al. Algorithmic Approach for Clinical Management of Chronic Spinal Pain // Pain Physician. - 2009; 12: 225-64.
  11. De Palma M., Ketchum J., Saullo T. What is the source of chronic low back pain and does age play a role? // Pain Med. - 2011; 12 (2): 224-33.
  12. Васильев А.С., Васильева В.В. Междисциплинарные аспекты ведения пациентов с синдромом торакалгии // Кремлевская медицина. Клинический вестник. - 2013; 3: 62-5.
  13. Парфенов В.А., Батышева Т.Т. Боли в спине: болезненный мышечный спазм и его лечение миорелаксантами // Лечащий врач. - 2013; 4: 16-8.
  14. Drug Monograph. Baclofen https://www.clinicalkey.com/#!/content/drug_ monograph/6-s2.0-56
  15. Katz P., Gerson L., Vela M. Guidelines for the diagnosis and management of gastroesophageal reflux disease // Am. J. Gastroenterol. - 2013; 108: 308-28.
  16. Fromm G., Terrence C., Chattha A. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up // Ann. Neurol. - 1984; 15: 240-4.
  17. Васильева В.В., Шмырев В.И., Васильев А.С. Мышечнотонический дисбаланс у детей первых недель и месяцев жизни // Врач. - 2010; 1: 8-10.
  18. Duncan G., Shahani B., Young R. An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double-blind, cross-over study // Neurology. - 1976; 26: 441-6.
  19. Feldman R., Kelly-Hayes M., Conomy J. et al. Baclofen for spasticity in multiple sclerosis.Double-blind crossover and three-year study // Neurology. -1978; 28: 1094-8.
  20. Sawa G., Paty D. The use of baclofen in treatment of spasticity in multiple sclerosis // Can. J. Neurol. Sci. - 1979; 6: 351-4.
  21. Milla P., Jackson A. A controlled trial of baclofen in children with cerebral palsy // J. Int. Med. Res. - 1977; 5: 398-404.
  22. Medaer R., Hellebuyk H., Van den Brande E. et al. Treatment of spasticity due to stroke. A double-blind, cross-over trial comparing baclofen with placebo // Acta Ther. - 1991; 17: 323-31.
  23. Smolenski Ch., Muff S., Smolenski-Kautz S. A double-blind comparative trial of a new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis // Curr. Med. Res. Opin. - 1981; 7: 374-83.
  24. Stien R., Nordal H., Oftedal S. et al. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine* compared with baclofen // Acta Neurol. Scand. - 1987; 75: 190-4.
  25. Medici M., Pebet M., Ciblis D. A double-blind, long-term study of tizanidine (‘Sirdalud’)in spasticity due to cerebrovascular lesions // Curr. Med. Res. Opin. -1989; 11: 398-405.
  26. Hoogstraten M., van der Ploeg R., vd Burg W. et al. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients // Acta Neurol. Scand. - 1988; 77: 224-30.
  27. Bresolin N., Zucca C., Pecori A. Efficacy and tolerability of eperisone and baclofen in spastic palsy: A double-blind randomized trial // Adv. Ther. - 2009; 26: 563-73.
  28. Baclofen Tablet package insert. Sellersville, PA: Teva Pharmaceuticals USA, 2010 Jun.
  29. Lioresal (baclofen) injection package insert. Minneapolis, MN: Medtronic, Inc., 2016 Sep.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies